ORGANIGRAM HOLDINGS INC. (OGI) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ORGANIGRAM HOLDINGS INC. Do?
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada. ORGANIGRAM HOLDINGS INC. (OGI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Beena G. Goldenberg and employs approximately 860 people. With a market capitalization of $183M, OGI is one of the notable companies in the Healthcare sector.
ORGANIGRAM HOLDINGS INC. (OGI) Stock Rating — Reduce (April 2026)
As of April 2026, ORGANIGRAM HOLDINGS INC. receives a Reduce rating with a composite score of 38.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OGI ranks #2,975 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ORGANIGRAM HOLDINGS INC. ranks #425 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
OGI Stock Price and 52-Week Range
ORGANIGRAM HOLDINGS INC. (OGI) currently trades at $1.40. The stock lost $0.04 (2.8%) in the most recent trading session. The 52-week high for OGI is $2.24, which means the stock is currently trading -37.5% from its annual peak. The 52-week low is $0.85, putting the stock 64.7% above its annual trough. Recent trading volume was 366K shares, suggesting relatively thin trading activity.
Is OGI Overvalued or Undervalued? — Valuation Analysis
ORGANIGRAM HOLDINGS INC. (OGI) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.75x, versus the sector average of 2.75x. The price-to-sales ratio is 0.29x, compared to 1.66x for the average Healthcare stock.
At current multiples, ORGANIGRAM HOLDINGS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ORGANIGRAM HOLDINGS INC. Profitability — ROE, Margins, and Quality Score
ORGANIGRAM HOLDINGS INC. (OGI) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -28.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -17.6% versus the sector average of -33.1%.
On a margin basis, ORGANIGRAM HOLDINGS INC. reports gross margins of 23.3%, compared to 71.5% for the sector. The operating margin is -7.8% (sector: -66.1%). Net profit margin stands at -10.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
OGI Debt, Balance Sheet, and Financial Health
ORGANIGRAM HOLDINGS INC. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $20M.
OGI has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ORGANIGRAM HOLDINGS INC. is 44/100, reflecting average volatility within the normal range for its sector.
ORGANIGRAM HOLDINGS INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ORGANIGRAM HOLDINGS INC. reported revenue of $164M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-18M. Gross margin was 23.3%. Operating income came in at $-13M.
In FY 2025, ORGANIGRAM HOLDINGS INC. reported revenue of $164M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-18M. Gross margin was 23.3%. Revenue grew 38.4% year-over-year compared to FY 2024. Operating income came in at $-13M.
In FY 2024, ORGANIGRAM HOLDINGS INC. reported revenue of $118M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-34M. Gross margin was 29.7%. Operating income came in at $-26M.
In FY 2022, ORGANIGRAM HOLDINGS INC. reported revenue of $100M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-11M. Gross margin was 9.0%. Revenue grew 59.2% year-over-year compared to FY 2021. Operating income came in at $-33M.
Over the past 8 quarters, ORGANIGRAM HOLDINGS INC. has demonstrated a growth trajectory, with revenue expanding from $10M to $164M. Investors analyzing OGI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
OGI Dividend Yield and Income Analysis
ORGANIGRAM HOLDINGS INC. (OGI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
OGI Momentum and Technical Analysis Profile
ORGANIGRAM HOLDINGS INC. (OGI) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.
OGI vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ORGANIGRAM HOLDINGS INC. (OGI) ranks #425 out of 838 stocks based on the Blank Capital composite score. This places OGI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing OGI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OGI vs S&P 500 (SPY) comparison to assess how ORGANIGRAM HOLDINGS INC. stacks up against the broader market across all factor dimensions.
OGI Next Earnings Date
No upcoming earnings date has been announced for ORGANIGRAM HOLDINGS INC. (OGI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy OGI? — Investment Thesis Summary
The quantitative profile for ORGANIGRAM HOLDINGS INC. suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 22/100 indicates premium valuation.
In summary, ORGANIGRAM HOLDINGS INC. (OGI) earns a Reduce rating with a composite score of 38.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OGI stock.
Related Resources for OGI Investors
Explore more research and tools: OGI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OGI head-to-head with peers: OGI vs AZN, OGI vs SLGL, OGI vs VMD.